Biote Q3 revenue $42M (+18% YoY); expects upper end of 2022 guidance

biote Corp.

2022-Q3 EPS reported $0.75 revenue$120,472,000

Revenue $42.0M, up 18% YoY; net loss $(6.3)M, GAAP diluted EPS $(1.74) due to transaction costs.
Adjusted EBITDA $12.2M (+19% YoY); expects upper end of 2022 revenue $160-$166M and adj. EBITDA $47-$51M.
Gross margin improved to 68.2% from 65.4% on favorable product mix.
Operating income $7.8M, down 13% due to $3.1M transaction and legal costs.
Cash from operations $6.4M in Q3; sales force expansion on track.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

biote Corp. reported the third quarter ended September 30, 2022 results: revenue $42.0 million, net income $(6.3) million, EPS $(1.74). Guidance reaffirmed.

Period: the third quarter ended September 30, 2022
Revenue: $42.0 million
Net income: $(6.3) million
EPS: $(1.74)
Guidance: reaffirmed
Result: reported results

Exact text from the filing

set forth by specific reference in such a filing. --- EX-99.1 (EX-99.1) --- EX-99.1 Exhibit 99.1 Biote Reports Third Quarter Financial Results Strong Third Quarter Revenue of $42 million Driven by Growth in Procedures 2022 Revenue and Adjusted EBITDA Expected at Upper End of Guidance IRVING, TX – November 8, 2022 - Biote (NASDAQ: BTMD), a leading provider of

View on SEC.gov

59 earnings releases filed in the last 30 days. Browse all earnings releases →

biote Corp. filing history →

Source: SEC EDGAR

accession 0001193125-22-280186

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.